Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The Pulmonary Embolism International Thrombolysis Study (PEITHO) was a large multinational, randomized, investigator initiated and academically sponsored trial which set out to determine whether normotensive, intermediate-risk patients with confirmed pulmonary embolism (PE) and right ventricular dysfunction, detected by echocardiography or CT, plus evidence of myocardial injury indicated by a positive troponin test, may benefit from early thrombolytic treatment (tenecteplase).
The primary efficacy end point was a clinical composite end point of all-cause mortality or haemodynamic collapse within the first 7 days. Safety end points were total strokes (intracranial haemorrhage or ischaemic stroke) within 7 days, and major bleeds (other than intracranial haemorrhage) within 7 days.
PEITHO was conducted at 76 sites in 13 countries and enrolled a total of 1006 patients. The study was funded through grants from the German government (Federal Ministry of Education and Research) and from the French Ministry of Health, and supported by Boehringer Ingelheim. It was published in the New England Journal of Medicine in 2014
Two-year follow-up of randomized patients has also been completed; the results will be available shortly.
© 2017 European Society of Cardiology. All rights reserved